MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/10781552251340014

Медицинская библиотека · Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2025

Complete color vision loss in a patient with metastatic melanoma of the skin treated with nivolumab-relatlimab.

Alchaikh Hassan Ruba, Vu Anderson, Tsai Henry, Dasanu Constantin A

СтатьяКлинический случайПеревод в очереди

Аннотация

IntroductionThe combination nivolumab-relatlimab has demonstrated therapeutic benefits for patients with metastatic melanoma. However, its adverse effects can affect various organs, including the eye.Case reportWe present the case of an 80-year-old man who developed complete color blindness after the 2nd dose of nivolumab-relatlimab for advanced cutaneous melanoma. He also had significant blurry vision. Fundoscopy identified bilateral serous macular detachment. Ocular coherence tomography confirmed serous infiltration within the macula. After a thorough investigation, causality assessment linked this retinal effect to nivolumab-relatlimab (probable relationship via Naranjo criteria).Management and outcomeThe patient was treated with corticosteroids, intravenous immunoglobulin (IVIG), rituximab, and plasmapheresis, with improvement in blurry vision. However, he continued to experience persistent absence of color perception ("black and white vision") at a follow-up visit six months later.Discussion/conclusionFurther studies are necessary to understand the exact pathophysiology of this process. We hypothesize that it involves direct toxicity to the photoreceptors or retinal ganglion cells, leading to irreversible color vision loss. Effective strategies for preventing this significant, life-changing toxic effect of nivolumab-relatlimab should be sought.

Для цитирования: Alchaikh Hassan Ruba, Vu Anderson, Tsai Henry, Dasanu Constantin A. Complete color vision loss in a patient with metastatic melanoma of the skin treated with nivolumab-relatlimab.. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2025. DOI: 10.1177/10781552251340014.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.